Two biotech companies testing high-risk treatments for fatal cancers are approaching a day of reckoning on Monday, when doctors will convene to advise the Food and Drug Administration on whether their drugs are worth approving. Investors have already voted: both Genta (nasdaq: GNTA - news - people ) and Allos Therapeutics (nasdaq: ALTH - news - people ) got 40%-plus haircuts today, making them the top two percentage losers on the Nasdaq.
